ProfileGDS5678 / 1434077_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 33% 33% 39% 35% 30% 32% 33% 31% 34% 34% 31% 33% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7629332
GSM967853U87-EV human glioblastoma xenograft - Control 22.7471333
GSM967854U87-EV human glioblastoma xenograft - Control 32.7565133
GSM967855U87-EV human glioblastoma xenograft - Control 42.8299839
GSM967856U87-EV human glioblastoma xenograft - Control 52.7524835
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7658430
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7692532
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7447233
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6799331
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7593834
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7546534
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6840431
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7610433
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9304641